lthough the initial interest in the field of leukotriene (LT) research was focused on their potent bronchoconstrictive effects, subsequent studies have suggested LTs as key mediators in several inflammatory diseases. Genetic variations within the enzymes transforming arachidonic acid into LTs (Figure) have for example been associated with atherosclerosis and an increased risk of cardiovascular events. 1 
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Leukotriene C 4 synthase (LTC 4 S; Figure) is a microsomal glutathione-S-transferase (mGST), which conjugates LTA 4 with glutathione. 2 The product, LTC 4 , shares its following enzymatic steps with glutathione to yield LTD 4 and LTE 4 ( Figure) . These 3 LTs, collectively referred to as the cysteinyl-LTs, exert their actions by means of at least 2 subclasses of CysLT receptors (Figure) expressed in airway and vessels, as well as on inflammatory cells. 3 The CysLT 1 receptor is the target for the clinically used antileukotrienes in asthma: montelukast, zafirlukast and pranlukast ( Figure) . The gene for LTC 4 S is mapped to the chromosome region 5q35, which is close to the cluster of cytokine genes associated with Th2 responses and asthma. 2 In this issue of Arteriosclerosis, Thrombosis and Vascular Biology, Freiberg and coworkers have explored the association of ischemic stroke with polymorphisms in the proximity of the LTC 4 S gene. 4 A single nucleotide polymorphism (SNP) in the LTC 4 S promoter was initially discovered in aspirin-intolerant asthmatics (AIA), a patient group particularly sensitive to the LTC 4 -induced bronchoconstriction. 5 In the latter study, an adenine (A) to cytosine (C) conversion 444 bp upstream in 5Ј-flanking region of the LTC 4 S gene ( Figure) was overrepresented in AIA. 5 Subsequent studies, which either confirmed 6 or did not replicate 7-9 the genotype effect, in addition suggested that the Ϫ444 genotype predicted the sensitivity to antiasthmatic CysLT 1 receptor antagonists. 6, 7 A second SNP at Ϫ1072 (Figure) , with a lower frequency (7%) compared with the Ϫ444 SNP (29%), has also been described within the LTC 4 S promoter ( Figure) but was not associated with asthma. 8 In contrast to the overrepresented Ϫ444 C in AIA, 5 the study by Freiberg et al associates the same polymorphism with a decreased risk for ischemic cerebrovascular events. 4 Because LTC 4 synthesis has been reported to be enhanced in calcium inophore-stimulated eosinophils derived from carriers of C at the Ϫ444 locus, 6 the main question raised by those results is hence whether cysteinyl-LTs are protective or deleterious in cerebrovascular disease. Although genotyping without evaluation of the functional consequences cannot give the verdict to cysteinyl-LTs as being angels or demons, some interesting hypotheses can be generated by integrating findings in cardiovascular cohorts with those previously reported in the context of asthma.
Whereas asthmatics with the genotype described as protective for cerebrovascular events 4 display an increased cysteinyl-LT biosynthesis, 6 the genotype effect in stroke patients remains unknown given the lack of LT measurements in the studies evaluating genetic LTC 4 S variations in the context of cardiovascular disease. 4, 10 Furthermore, the rationale for the initial studies of AIA was based on the selective upregulation of LTC 4 S in bronchial biopsies from these patients. 11 In contrast, human carotid atherosclerotic lesions have been reported not to express increased levels of LTC 4 S compared with healthy vessels. 12 Nevertheless, although LTC 4 S may not be as profoundly upregulated in the vascular wall as has been reported in bronchial mucosa, the atherosclerotic lesion is indeed a site of local cysteinyl-LT production. 13 Because the cellular composition of the eosinophilic bronchial inflammation in asthmatics may differ from the more macrophage-dominated atherosclerotic lesion, a cell-specific transcriptional regulation of the LTC 4 S gene cannot be excluded as explanation for the diverging promoter polymorphism-induced risk in asthma and cerebrovascular disease.
Furthermore, the finding that the Ϫ444 A to C conversion provides significant protection against stroke 4 is also in contrast to another recent study reporting a significant correlation of the same SNP with increased coronary calcium and carotid intima media thickness (IMT) in women. 10 These apparent contradictory results raise the possibility of a timedependent role of cysteinyl-LTs in cardiovascular disease. Whereas progression of atherosclerosis (measured as coronary calcium and IMT 10 ) potentially could be promoted by cysteinyl-LTs, plaque rupture and stroke 4 may be prevented if cysteinyl-LT production increases. One possible mechanism in this time-dependency could be related to cysteinyl-LTinduced effects on vascular smooth muscle cells (SMCs). Cysteinyl-LTs induce SMC proliferation and intimal hyperplasia 1 and may through this mechanism of action act as demons in the atherosclerosis process. However, could cysteinyl-LTs subsequently act as angels by stimulating SMCs to stabilize the plaque?
The latter question remains unanswered, because the exact role and time-course of the cysteinyl-LT-induced effects on SMCs and on other cells within the atherosclerotic lesion today are largely unknown. In contrast, the other arm of the LT cascade, namely the chemotactic LTB 4 (Figure) , has been more extensively studied in this context. Selective inhibition of LTB 4 signaling through BLT receptors has shown beneficial effects in different animal models of atherosclerosis. 1, 14 Another tempting hypothesis is that an upregulation of LTC 4 S potentially could shunt LTA 4 metabolism toward LTC 4 and hence diminish LTB 4 production (Figure) . Again, in the absence of explorations of the functional genotype effect, this latter suggestion remains rather speculative for the moment.
Finally, it should be pointed out that LTC 4 S is only 1 of 3 enzymes which can conjugate LTA 4 with glutathione to cysteinyl-LTs. Also other enzymes within the mGST family can participate in cysteinyl-LT biosynthesis, 2 but have not yet been explored in the context of atherosclerosis.
A potential stroke-protective effect of proinflammatory mediators is definitively an exciting thought. However, although promoter polymorphisms only can provide a suggestion of such a link, further mechanistic studies are needed before judging the cysteinyl-LTs as either angels or demons in cerebrovascular disease.
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